Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 381

1.

Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women.

Skates SJ, Menon U, MacDonald N, Rosenthal AN, Oram DH, Knapp RC, Jacobs IJ.

J Clin Oncol. 2003 May 15;21(10 Suppl):206s-210s.

PMID:
12743136
2.

A randomized study of screening for ovarian cancer: a multicenter study in Japan.

Kobayashi H, Yamada Y, Sado T, Sakata M, Yoshida S, Kawaguchi R, Kanayama S, Shigetomi H, Haruta S, Tsuji Y, Ueda S, Kitanaka T.

Int J Gynecol Cancer. 2008 May-Jun;18(3):414-20. Epub 2007 Jul 21.

PMID:
17645503
4.

Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study.

Tailor A, Bourne TH, Campbell S, Okokon E, Dew T, Collins WP.

Ultrasound Obstet Gynecol. 2003 Apr;21(4):378-85.

5.

Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.

Menon U, Talaat A, Rosenthal AN, Macdonald ND, Jeyerajah AR, Skates SJ, Sibley K, Oram DH, Jacobs IJ.

BJOG. 2000 Feb;107(2):165-9.

6.

Status of tumor markers in ovarian cancer screening.

Bast RC Jr.

J Clin Oncol. 2003 May 15;21(10 Suppl):200s-205s. Review.

PMID:
12743135
7.

[Predictive value of CA 125 in detection of ovarian cancer in pre- and postmenopausal patients].

Grzybowski W, Beta J, Fritz A, Durczyński A, Bidziński M, Grabiec M, Jakimiuk AJ.

Ginekol Pol. 2010 Jul;81(7):511-5. Polish.

PMID:
20825052
8.

Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.

Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):306-18. Erratum in: Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1583.

9.

The role of CA 125 in screening for ovarian cancer.

Rosenthal AN, Jacobs IJ.

Int J Biol Markers. 1998 Oct-Dec;13(4):216-20. Review.

PMID:
10228904
10.

Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.

Hermsen BB, von Mensdorff-Pouilly S, Berkhof J, van Diest PJ, Gille JJ, Menko FH, Blankenstein MA, Kenemans P, Verheijen RH.

J Clin Oncol. 2007 Apr 10;25(11):1383-9.

11.

Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer.

Chang HW, Lee SM, Goodman SN, Singer G, Cho SK, Sokoll LJ, Montz FJ, Roden R, Zhang Z, Chan DW, Kurman RJ, Shih IeM.

J Natl Cancer Inst. 2002 Nov 20;94(22):1697-703.

12.

Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening.

Cane P, Azen C, Lopez E, Platt LD, Karlan BY.

Gynecol Oncol. 1995 May;57(2):240-5.

PMID:
7729742
13.

Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer.

Menon U, Skates SJ, Lewis S, Rosenthal AN, Rufford B, Sibley K, Macdonald N, Dawnay A, Jeyarajah A, Bast RC Jr, Oram D, Jacobs IJ.

J Clin Oncol. 2005 Nov 1;23(31):7919-26.

14.

CA 125 as a screening test for ovarian cancer.

Hakama M, Stenman UH, Knekt P, Järvisalo J, Hakulinen T, Maatela J, Aromaa A.

J Med Screen. 1996;3(1):40-2.

PMID:
8861050
15.

Pre-operative evaluation of ovarian mass: risk of malignancy index.

Asif N, Sattar A, Dawood MM, Rafi T, Aamir M, Anwar M.

J Coll Physicians Surg Pak. 2004 Mar;14(3):128-31.

PMID:
15228841
16.

Significance of a single CA 125 assay combined with ultrasound in the early detection of ovarian and endometrial cancer.

Vuento MH, Stenman UH, Pirhonen JP, Mäkinen JI, Laippala PJ, Salmi TA.

Gynecol Oncol. 1997 Jan;64(1):141-6.

PMID:
8995563
17.

Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women.

Jeyarajah AR, Ind TE, Skates S, Oram DH, Jacobs IJ.

Cancer. 1999 May 1;85(9):2068-72.

PMID:
10223249
18.

Risk-of-malignancy index in preoperative evaluation of clinically restricted ovarian cancer.

Torres JC, Derchain SF, Faundes A, Gontijo RC, Martinez EZ, Andrade LA.

Sao Paulo Med J. 2002 May 2;120(3):72-6.

19.

Factors influencing serum CA125II levels in healthy postmenopausal women.

Pauler DK, Menon U, McIntosh M, Symecko HL, Skates SJ, Jacobs IJ.

Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):489-93.

20.

The value of cancer antigen 125 (CA 125) during treatment and follow-up of patients with ovarian cancer.

de Bruijn HW, van der Zee AG, Aalders JG.

Curr Opin Obstet Gynecol. 1997 Feb;9(1):8-13. Review.

PMID:
9090475
Items per page

Supplemental Content

Write to the Help Desk